S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:IRIX

IRIDEX Stock Forecast, Price & News

$1.92
+0.04 (+2.13 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.83
Now: $1.92
$1.92
50-Day Range
$1.67
MA: $1.80
$1.97
52-Week Range
$1.22
Now: $1.92
$4.24
Volume130,394 shs
Average Volume47,293 shs
Market Capitalization$26.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.
IRIDEX logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
Current SymbolNASDAQ:IRIX
CUSIPN/A
Phone650-940-4700
Employees94

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.45 million
Book Value$1.23 per share

Profitability

Net Income$-8,810,000.00

Miscellaneous

Market Cap$26.68 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$1.92
+0.04 (+2.13 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IRIDEX (NASDAQ:IRIX) Frequently Asked Questions

How has IRIDEX's stock been impacted by Coronavirus?

IRIDEX's stock was trading at $1.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IRIX shares have decreased by 2.5% and is now trading at $1.92.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of IRIDEX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IRIDEX
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IRIDEX?

Wall Street analysts have given IRIDEX a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IRIDEX wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for IRIDEX
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) posted its quarterly earnings data on Monday, November, 9th. The medical equipment provider reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.06. IRIDEX had a negative return on equity of 38.67% and a negative net margin of 21.54%.
View IRIDEX's earnings history
.

What price target have analysts set for IRIX?

2 equities research analysts have issued 12 month target prices for IRIDEX's stock. Their forecasts range from $4.00 to $4.00. On average, they expect IRIDEX's share price to reach $4.00 in the next year. This suggests a possible upside of 108.3% from the stock's current price.
View analysts' price targets for IRIDEX
.

Are investors shorting IRIDEX?

IRIDEX saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 208,200 shares, an increase of 11.9% from the October 31st total of 186,100 shares. Based on an average daily trading volume, of 41,400 shares, the short-interest ratio is currently 5.0 days. Approximately 1.8% of the shares of the stock are short sold.
View IRIDEX's Short Interest
.

Who are some of IRIDEX's key competitors?

What other stocks do shareholders of IRIDEX own?

Who are IRIDEX's key executives?

IRIDEX's management team includes the following people:
  • Mr. David I. Bruce, Pres, CEO & Director (Age 61, Pay $330.28k)
  • Mr. Patrick Mercer, Chief Operating Officer (Age 48, Pay $356.52k)
  • Mr. Fuad Ahmad, Interim Chief Financial Officer (Age 50)
  • Ms. Leigh Salvo, Head of Investor Relations

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (4.53%), Isthmus Partners LLC (1.64%) and Perkins Capital Management Inc. (0.75%). Company insiders that own IRIDEX stock include Robert Earle Grove, Scott Shuda and William M Moore.
View institutional ownership trends for IRIDEX
.

Which institutional investors are selling IRIDEX stock?

IRIX stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc..
View insider buying and selling activity for IRIDEX
.

Which institutional investors are buying IRIDEX stock?

IRIX stock was bought by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., and Isthmus Partners LLC. Company insiders that have bought IRIDEX stock in the last two years include Robert Earle Grove, Scott Shuda, and William M Moore.
View insider buying and selling activity for IRIDEX
.

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $1.92.

How big of a company is IRIDEX?

IRIDEX has a market capitalization of $26.68 million and generates $43.45 million in revenue each year. The medical equipment provider earns $-8,810,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. IRIDEX employs 94 workers across the globe.

What is IRIDEX's official website?

The official website for IRIDEX is www.iridex.com.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.